Sotio’s SOT-106 designated orphan drug for soft tissue sarcoma

Sotio Biotech AS’s SOT-106 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcoma and fast track designation for the treatment of osteosarcoma. This means that SOT-106 now has both orphan drug and fast…

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

1. BioWorld Articles 3h ago
   Sotio’s SOT-106 designated orphan drug for soft tissue sarcoma ↗